The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?
Chronic kidney disease (CKD) is a global health burden that affects close to one billion individuals. As many healthcare systems struggle to accommodate existing patients, CKD incidence and related costs are projected to continue rising. Based on a systematic search, this narrative review offers an...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/15/6/809 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849431941626986496 |
|---|---|
| author | Sajjad Biglari Harald Mischak Joachim Beige Agnieszka Latosinska Justyna Siwy Mirosław Banasik |
| author_facet | Sajjad Biglari Harald Mischak Joachim Beige Agnieszka Latosinska Justyna Siwy Mirosław Banasik |
| author_sort | Sajjad Biglari |
| collection | DOAJ |
| description | Chronic kidney disease (CKD) is a global health burden that affects close to one billion individuals. As many healthcare systems struggle to accommodate existing patients, CKD incidence and related costs are projected to continue rising. Based on a systematic search, this narrative review offers an in-depth assessment of advances in CKD pharmacotherapy published between 2020 and 2025, with a specific emphasis on drug combinations. Various treatment approaches for CKD exist, many of them targeting different mechanisms. Therefore, combining multiple medications could provide patients with better outcomes, though this comes with the risk of increased adverse effects and unnecessary costs. Alternatively, using biomarkers presents an opportunity to ascertain the most appropriate treatments specifically tailored to an individual’s molecular profile, thus personalizing CKD management. The second part of this review presents the current state-of-the-art methods to guide CKD therapy based on markers predicting treatment response. Collectively, this review presents possible pathways toward more effective CKD treatment. |
| format | Article |
| id | doaj-art-889640028bf445f6bf52caa080fd4767 |
| institution | Kabale University |
| issn | 2218-273X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-889640028bf445f6bf52caa080fd47672025-08-20T03:27:29ZengMDPI AGBiomolecules2218-273X2025-06-0115680910.3390/biom15060809The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?Sajjad Biglari0Harald Mischak1Joachim Beige2Agnieszka Latosinska3Justyna Siwy4Mirosław Banasik5Mosaiques Diagnostics GmbH, 30659 Hannover, GermanyMosaiques Diagnostics GmbH, 30659 Hannover, GermanyKuratorium for Dialysis and Transplantation (KfH) Leipzig, 04129 Leipzig, GermanyMosaiques Diagnostics GmbH, 30659 Hannover, GermanyMosaiques Diagnostics GmbH, 30659 Hannover, GermanyDepartment of Nephrology, Transplantation Medicine and Internal Diseases Institute of Internal Diseases, Wroclaw Medical University, 50-551 Wroclaw, PolandChronic kidney disease (CKD) is a global health burden that affects close to one billion individuals. As many healthcare systems struggle to accommodate existing patients, CKD incidence and related costs are projected to continue rising. Based on a systematic search, this narrative review offers an in-depth assessment of advances in CKD pharmacotherapy published between 2020 and 2025, with a specific emphasis on drug combinations. Various treatment approaches for CKD exist, many of them targeting different mechanisms. Therefore, combining multiple medications could provide patients with better outcomes, though this comes with the risk of increased adverse effects and unnecessary costs. Alternatively, using biomarkers presents an opportunity to ascertain the most appropriate treatments specifically tailored to an individual’s molecular profile, thus personalizing CKD management. The second part of this review presents the current state-of-the-art methods to guide CKD therapy based on markers predicting treatment response. Collectively, this review presents possible pathways toward more effective CKD treatment.https://www.mdpi.com/2218-273X/15/6/809chronic kidney diseasetherapeutic interventionscombination therapypersonalized medicinebiomarker-guided therapytreatment response prediction |
| spellingShingle | Sajjad Biglari Harald Mischak Joachim Beige Agnieszka Latosinska Justyna Siwy Mirosław Banasik The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention? Biomolecules chronic kidney disease therapeutic interventions combination therapy personalized medicine biomarker-guided therapy treatment response prediction |
| title | The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention? |
| title_full | The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention? |
| title_fullStr | The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention? |
| title_full_unstemmed | The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention? |
| title_short | The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention? |
| title_sort | future of chronic kidney disease treatment combination therapy polypill or biomarker guided personalized intervention |
| topic | chronic kidney disease therapeutic interventions combination therapy personalized medicine biomarker-guided therapy treatment response prediction |
| url | https://www.mdpi.com/2218-273X/15/6/809 |
| work_keys_str_mv | AT sajjadbiglari thefutureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT haraldmischak thefutureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT joachimbeige thefutureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT agnieszkalatosinska thefutureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT justynasiwy thefutureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT mirosławbanasik thefutureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT sajjadbiglari futureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT haraldmischak futureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT joachimbeige futureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT agnieszkalatosinska futureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT justynasiwy futureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention AT mirosławbanasik futureofchronickidneydiseasetreatmentcombinationtherapypolypillorbiomarkerguidedpersonalizedintervention |